Efficacy of pembrolizumab in the first-line treatment of patients with metastatic NSCLC and high PD-L1 expression was assessed in a randomised multicentre, open-label, controlled KEYNOTE-024 study. Here, CD274 is linked to non-small cell lung carcinoma.